© 2025 CellCarta - All rights reserved.
Request a Consultation
CellCarta is a global contract research organization (CRO), with its Lake Forest site delivering specialized support to early stage programs.
We deliver rapid, high-quality histopathology, IHC assay development, and ADC biomarker data — so your team can move forward with confidence.
CellCarta Lake Forest: CRO in California.
✔ Histopathology Lab
✔ ADC Biomarker Experts
✔ In-house biobank
✔ Global CRO network
"As we advance our next-generation ADCs into phase 1, our success depends heavily on choosing the right CRO partners and CellCarta clearly stood out. CellCarta was one of very few CROs able to deliver the full scope of biomarker work we required under one roof. For a small team, that integrated capability makes our lives a lot easier."
Senior Director, Translational Medicine · ADC Biotech Company
From early research through CDx Development
CellCarta supports highly customized biomarker strategies and large-scale global studies across the full biomarker continuum — from translational research through clinical development and companion diagnostic (CDx) advancement. Start fast in California and scale globally with CellCarta’s owned global laboratory network.
Speak with a Scientist
Ready to start developing your assay?
Connect directly with our Lake Forest, California team. Tell us about your program, and a CellCarta scientist will contact you to discuss how we can support you.
➜ Direct access to pathologists and project leads from day one
➜ Rapid turnaround for IHC assay development, ADC biomarker profiling, and preclinical histopathology services
➜ Flexible collaboration that adapts as your early-stage program evolves
➜ Start fast in CellCarta Lake Forest — scale globally across our owned CRO network
Trusted by Our Clients
The CellCarta California Expertise
Speed Without Compromising Quality
Whether you need de novo IHC assay development or biomarker profiling for specific modalities like ADCS, we can deliver pathologist-validated data on early-stage timelines.
The Lake Forest Expertise
Flexibility for Programs That Evolve
As study requirements evolve, we adapt protocols, scope, and timelines to match your scientific direction. Whether your program expands, pivots, or accelerates, we are built to flex with it.
The Lake Forest Expertise
Why teams choose our California site: speed, flexibility, scientific partnership, and confidence in your data, backed by our global CRO network
CellCarta is a global contract research organization (CRO), and its Lake Forest site provides specialized support to early-stage biotech and pharmaceutical companies with histopathology, IHC assay development, preclinical pathology, and ADC biomarker profiling services.
The rigour and quality of your early-stage data are critical to program success. Our California laboratory delivers rapid, confident decisions — with the scientific partnership and flexibility your program needs at every stage.
Direct Scientific Partnership
Work as one team with our scientists and pathologists — with real-time updates and meaningful dialogue.
The Lake Forest Expertise
In-house Biobank Access
Immediate specimen availability eliminates sourcing delays and accelerates project initiation.
The Lake Forest Expertise
Confidence in Your Data
Scientific rigor and quality control processes are at the center of every project — delivering high-quality, reliable results from day one.
The Lake Forest Expertise
Built for Global Expansion
Start locally and transition seamlessly across CellCarta’s owned global laboratory network as your program advances.
The Lake Forest Expertise
The CellCarta California Expertise
Trusted by the 17 of the top 20 pharma companies
20 years supporting Phase 1, Phase 2 and Phase 3 programs
From concept to validated histopathology assay in under 3 months.
Platform Agnostic: Dako, Leica, Ventana, Sakura and now the COMET from Lunaphore.
Specialized in ADC biomarker profiling
Start Fast in California. Scale Globally with CellCarta.
IHC Assay Development & Histopathology CRO Services
Our Lake Forest laboratory provides immunohistochemistry (IHC) and immunofluorescence (IF) services for early-stage biotech and pharma programs. Whether you need de novo assay design, are interested in singleplex or multiplex IHC (mIHC), or multiplexed immunofluorescence (mIF) panels, our pathologist-led team delivers validated results on early-stage timelines.
We can take your assay from concept to validated protocol in under 3 months.
A Specialized Contract Research Organization for Biotech and Pharma
Not all contract research organizations are built the same. CellCarta is a global CRO — purpose-built for biomarker science. Our Lake Forest specialized histopathology team delivers the focused scientific expertise and direct pathologist access that early-stage biotech and pharma teams need to move faster and with greater confidence.
Scientific Specialization
Deep expertise in biomarker strategy, IHC assay development, ADC biomarker profiling, and histopathology
Direct Access, No Layers
Work directly with scientists and pathologists from day one
Direct Access, No Layers
Work directly with scientists and pathologists from day one
Built for Early-Stage Programs
Speed, flexibility, and precision for early-stage biotech and pharma programs.
Why teams choose our California site: speed, flexibility, scientific partnership, and confidence in your data, backed by our global CRO network
CellCarta is a global contract research organization (CRO), and its Lake Forest site provides specialized support to early-stage biotech and pharmaceutical companies with histopathology, IHC assay development, preclinical pathology, and ADC biomarker profiling services.
The rigour and quality of your early-stage data are critical to program success. Our California laboratory delivers rapid, confident decisions — with the scientific partnership and flexibility your program needs at every stage.
Speed Without Compromising Quality
Whether you need de novo assay development or pre-validated biomarker profiling, we deliver pathologist-validated data on early-stage timelines.
Flexibility for Programs That Evolve
As study requirements evolve, we adapt protocols, scope, and timelines to match your scientific direction. Whether your program expands, pivots, or accelerates, we are built to flex with it.
Confidence in Your Data
Scientific rigor and quality control processes are at the center of every project — delivering high-quality, reliable results from day one.
Built for Early-Stage Programs
Speed, flexibility, and precision for early-stage biotech and pharma
Direct Scientific Partnership
Work as one team with our scientists and pathologists — with real-time updates and meaningful dialogue.
In-house Biobank Access
Immediate specimen availability eliminates sourcing delays and accelerates project initiation.
Built for Global Expansion
Start locally and transition seamlessly across CellCarta’s owned global laboratory network as your program advances.
✔ IHC Assay Development
✔ Multiplex IHC (mIHC) & mIF
✔ Preclinical Histopathology
✔ Tissue Biomarker Analysis
Trusted by the 17 of the top 20 pharma companies
20 years. Supporting Phase 1, Phase 2, and Phase 3 programs.
From concept to validated histopathology assay in under 3 months.
Platform Agnostic: Dako, Leica, Ventana, Sakura and now the COMET from Lunaphore.
Specialized in ADC biomarker profiling